Bruker (NASDAQ:BRKR) Updates FY 2025 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.670-2.720 for the period, compared to the consensus earnings per share estimate of 2.680. The company issued revenue guidance of $3.5 billion-$3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $51.65 on Thursday. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a 12 month low of $48.07 and a 12 month high of $94.86. The company has a 50 day simple moving average of $57.88 and a two-hundred day simple moving average of $60.77. The stock has a market cap of $7.83 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 3.81 and a beta of 1.16.

Wall Street Analyst Weigh In

BRKR has been the subject of several research reports. UBS Group initiated coverage on shares of Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective for the company. TD Cowen decreased their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a report on Thursday, December 5th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Friday, January 17th. Finally, Bank of America lifted their target price on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $74.09.

Insider Buying and Selling

In related news, CEO Frank H. Laukien purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.